THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.11] ID: TIP-MED-000243 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Potassium Magnesium Citrate & Disodium Hydrogen Citrate

Active Ingredient / Scientific Identity: Potassium Magnesium Citrate & Disodium Hydrogen Citrate • Class: Systemic & Urinary Alkalinisers / Urolithiasis Inhibitors

⚖️ Compare Profile
Generic / Entity NamePotassium Magnesium Citrate & Disodium Hydrogen Citrate ([12.11])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassSystemic & Urinary Alkalinisers / Urolithiasis Inhibitors
Available Dosage FormsDisodium Hydrogen Citrate Oral Liquid: 1.25 g to 1.53 g per 5 mL (100 mL, 200 mL bottle). Potassium Citrate (1
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Contraindicated if eGFR <30 mL/min, oliguria, or acute kidney injury. Hepatic: Avoid in decompensated cirrhosis wit
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o🚨 Clinically High-Alert: Independent Dose & Route Verification Required

1. Clinical & Scientific Overview

Potassium Magnesium Citrate & Disodium Hydrogen Citrate (TIP-MED-000243, Reference Code [12.11]) is classified under Urological & Renal Stone Medicines (Ch 12) as a Systemic & Urinary Alkalinisers / Urolithiasis Inhibitors. Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.11], p. 160): Disodium Hydrogen Citrate: Citralka (Pfizer — 1.53 g/5 mL), Alkasol (Stadmed — 1.4 g/5 mL), Orikind; Potassium Magnesium Citrate: Potrate-MB6 (Intas), Orocit-K, Ston-1 — Strengths & Dosage Forms: Disodium Hydrogen Citrate Oral Liquid: 1.25 g to 1.53 g per 5 mL (100 mL, 200 mL bottle). Potassium Citrate (1100 mg = ~10 mEq K+) + Magnesium Citrate (375 mg) + Pyridoxine (20 mg) Oral Solution / ER Tablets.
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.11], p. 160): Disodium Hydrogen Citrate: Citralka (Pfizer — 1.53 g/5 mL), Alkasol (Stadmed — 1.4 g/5 mL), Orikind; Potassium Magnesium Citrate: Potrate-MB6 (Intas), Orocit-K, Ston-1 — Strengths & Dosage Forms: Disodium Hydrogen Citrate Oral Liquid: 1.25 g to 1.53 g per 5 mL (100 mL, 200 mL bottle). Potassium Citrate (1100 mg = ~10 mEq K+) + Magnesium Citrate (375 mg) + Pyridoxine (20 mg) Oral Solution / ER Tablets.
Dosage Forms & Available Strengths:
Disodium Hydrogen Citrate Oral Liquid: 1.25 g to 1.53 g per 5 mL (100 mL, 200 mL bottle). Potassium Citrate (1100 mg = ~10 mEq K+) + Magnesium Citrate (375 mg) + Pyridoxine (20 mg) Oral Solution / ER Tablets.
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Citrate is metabolised to bicarbonate in the liver, raising urinary pH (6.5–7.2) to solubilise uric acid/cystine and chelating urinary calcium to inhibit calcium oxalate nucleation.

4. Therapeutic Indications & Evidence-Supported Uses

  • Prevention and dissolution of renal calculi (calcium oxalate, uric acid, and cystine nephrolithiasis), symptomatic relief of burning micturition (dysuria) in UTI, and urinary alkalinisation during uricosuric/allopurinol gout therapy

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Disodium Hydrogen Citrate Liquid: Adult 10–15 mL (2–3 teaspoons) diluted in 1 full glass (200 mL) of water TDS–QDS after meals; Paediatric (6–12 yr) 5 mL diluted in water BD–TDS. Potassium Magnesium Citrate: 10–15 mL diluted in water BD–TDS after meals (or 1–2 ER tablets BD).

Administration & Meal Timing: MUST be diluted in a full glass of water and taken 15–30 minutes AFTER meals to prevent gastric mucosal irritation and osmotic diarrhoea. | 2 to 4 times daily after meals and at bedtime.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Contraindicated if eGFR <30 mL/min, oliguria, or acute kidney injury. Hepatic: Avoid in decompensated cirrhosis with ascites.
Elimination & Renal Adjustment:
Renal: Contraindicated if eGFR <30 mL/min, oliguria, or acute kidney injury. Hepatic: Avoid in decompensated cirrhosis with ascites.
Hepatic Impairment Considerations:
Renal: Contraindicated if eGFR <30 mL/min, oliguria, or acute kidney injury. Hepatic: Avoid in decompensated cirrhosis with ascites.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • HYPERKALAEMIA vs SODIUM LOAD SELECTION RULE: Potassium Citrate preparations are CONTRAINDICATED in CKD Stage G4–G5 (eGFR <30 mL/min), hyperkalaemia (K+ >5.0 mEq/L), or with Spironolactone/ACEi/ARBs. Disodium Hydrogen Citrate delivers a high sodium load (~16 mmol Na+ per 10 mL) — avoid in severe heart failure, oedema, or uncontrolled hypertension!

Key Clinical Precautions: Renal: Contraindicated if eGFR <30 mL/min, oliguria, or acute kidney injury. Hepatic: Avoid in decompensated cirrhosis with ascites.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Mild nausea, abdominal bloating, loose stools (if taken undiluted), wax-matrix ghost tablet in stool (ER tablets).
  • Life-threatening hyperkalaemic cardiac arrhythmia (Potassium Citrate in CKD/MRA patients), fluid overload/pulmonary oedema (Disodium Hydrogen Citrate in HFrEF), metabolic alkalosis (over-alkalinisation >pH 7.5 precipitates calcium phosphate stones!).
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Potassium Citrate + ACEi/ARB/Spironolactone/Trimethoprim = severe hyperkalaemia
  • Urinary alkalinisation increases renal excretion of Salicylates/Phenobarbitone and decreases excretion of Quinolones/Ephedrine; aluminium antacids + citrate increase systemic Al3+ neurotoxicity in CKD!

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: NEVER swallow the liquid syrup neat — always mix the measured dose in 1 full glass of water and drink after food; drink 10–12 glasses of water daily to flush kidney crystals.
  • Meal & Clock Timing Instruction: MUST be diluted in a full glass of water and taken 15–30 minutes AFTER meals to prevent gastric mucosal irritation and osmotic diarrhoea. (2 to 4 times daily after meals and at bedtime.)
  • Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
  • Geriatric Dispensing Pearl: Schedule: Non-Schedule / Schedule H (Strength-dependent) | NLEM 2022: NFI 2026 Standard Formulary | Compendia: NFI 7th Ed 2026 / EAU Urolithiasis Guidelines

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Disodium Hydrogen Citrate Oral Liquid: 1.25 g to 1.53 g per 5 mL (100 mL, 200 mL bottle). Potassium Citrate (1100 mg = ~10 mEq K+) + Magnesium Citrate (375 mg) + Pyridoxine (20 mg) Oral Solution / ER Tablets.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.11] (p. 160)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.